Literature DB >> 11309313

An intracellular form of cathepsin B contributes to invasiveness in cancer.

A M Szpaderska1, A Frankfater.   

Abstract

Cathepsin B is a lysosomal cysteine proteinase whose expression and trafficking are frequently altered in cancer, and plasma membrane and secreted forms are thought to contribute to the invasive and metastatic properties of malignant tumors. We have manipulated the expression of cathepsin B in several tumor cell lines and measured their capacity to invade through a reconstituted extracellular (Matrigel) matrix. Transient expression of human cathepsin B in a poorly metastatic B16F1 murine melanoma variant produced a 3-5-fold increase in cathepsin B activity and a comparable increase in invasiveness. Stable antisense cathepsin B-expressing clones of the highly metastatic human melanoma A375M and prostate carcinoma PC3M cell lines produced 40-50% less cathepsin B than control cells and were proportionately less invasive. In contrast, manipulating cathepsin B levels had no effect on cell migration across an uncoated membrane. The anionic cathepsin B inhibitor (L-3-trans-propylcarbamoyloxirane-2-carbony)-L-isoleucyl-L-proline (CA-074), at a concentration of 1 microM, caused a nearly quantitative inhibition of extracellular cathepsin B but had no effect on Matrigel invasion. In contrast, the equally potent but less selective inhibitor, trans-epoxysuccinyl-L-leucylamino(4-guanidino)butane (E-64) inhibited invasion by 75%. Surprisingly, at a concentration of 10 microM, CA-074 slowly permeated the cells, causing an 80-95% inhibition of intracellular cathepsin B after 12 h, the duration of the invasion assay. The membrane-permeant cathepsin B inhibitor, CA-074 methyl ester, and the higher concentration of CA-074 that inhibited intracellular cathepsin B both significantly reduced Matrigel invasion. Collectively, these results identify an intracellular role for cathepsin B in matrix degradation. They also indicate that caution should be exercised in assuming that CA-074 is unable to enter cells when it is used to inhibit biological processes of long duration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11309313

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Acidic extracellular microenvironment promotes the invasion and cathepsin B secretion of PC-3 cells.

Authors:  Li Gao; You-Qiang Fang; Tian-Yu Zhang; Bo Ge; Rong-Jing Tang; Jie-Fu Huang; Lei-Ming Jiang; Ning Tan
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

3.  Nanoneedle-Based Materials for Intracellular Studies.

Authors:  Julia E Sero; Molly M Stevens
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Discovery of transcription factors and other candidate regulators of neural crest development.

Authors:  Meghan S Adams; Laura S Gammill; Marianne Bronner-Fraser
Journal:  Dev Dyn       Date:  2008-04       Impact factor: 3.780

Review 5.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

6.  Induction of cell death in neuroblastoma by inhibition of cathepsins B and L.

Authors:  Rita Colella; Guizhen Lu; Lisa Glazewski; Bruce Korant; Anjan Matlapudi; Matthew R England; Colin Craft; Christopher N Frantz; Robert W Mason
Journal:  Cancer Lett       Date:  2010-04-01       Impact factor: 8.679

7.  Cathepsin B carboxydipeptidase specificity analysis using internally quenched fluorescent peptides.

Authors:  Maria Helena S Cezari; Luciano Puzer; Maria Aparecida Juliano; Adriana K Carmona; Luiz Juliano
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

8.  Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.

Authors:  Rui Zhang; Jiyuan Yang; Monika Sima; Yan Zhou; Jindřich Kopeček
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

9.  Cystatin C deficiency promotes epidermal dysplasia in K14-HPV16 transgenic mice.

Authors:  Weifang Yu; Jian Liu; Michael A Shi; Jianan Wang; Meixiang Xiang; Shiro Kitamoto; Bing Wang; Galina K Sukhova; George F Murphy; Gabriela Orasanu; Anders Grubb; Guo-Ping Shi
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  Cystatin E/M suppresses legumain activity and invasion of human melanoma.

Authors:  Jon J Briggs; Mads H Haugen; Harald T Johansen; Adam I Riker; Magnus Abrahamson; Øystein Fodstad; Gunhild M Maelandsmo; Rigmor Solberg
Journal:  BMC Cancer       Date:  2010-01-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.